AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million




AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million

OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced the preliminary results of its previously announced rights offering (the “Rights Offering”) which expired at 5:00 p.m., Eastern Time, on March 3, 2026. The Company estimates that the Rights Offering will result in total subscriptions of approximately $1.8 million. The results of the Rights Offering are preliminary and subject to change pending finalization and verification by the Company and its subscription agent, Broadridge Corporate Issuer Solutions, LLC.

Each right entitled the holder to purchase one unit (“Unit”), at a subscription price of $1,000 per Unit, consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), and 2,000 Class G Common Stock Purchase Warrants to purchase the Company’s Common Stock (the “Warrants”).

The Company anticipates the closing of the Rights Offering will occur on or about March 6, 2026, subject to satisfaction or waiver of all conditions to closing. Upon the closing, the subscription agent will distribute, by way of direct registration in book-entry form or through the facilities of DTC, as applicable, shares of the Preferred Stock and Warrants to holders of rights who have validly exercised their rights and paid the subscription price in full. No physical stock or warrant certificates will be issued to such holders.

Maxim Group LLC acted as dealer-manager for the Rights Offering. Questions about the Rights Offering or requests for copies of the final prospectus may be directed to Maxim Group LLC at 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.

The Company’s registration statement on Form S-1 (Registration No. 333-292085) was declared effective by the Securities and Exchange Commission (“SEC”) on February 10, 2026. The prospectus relating to and describing the terms of the Rights Offering has been filed with the SEC as a part of the registration statement and is available on the SEC’s website at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AIM ImmunoTech

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

Forward Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the registration statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.

CONTACT: IR Contact:

JTC Team, LLC

Jenene Thomas

908.824.0775

AIM@jtcir.com

ICAN Poll: Overwhelming Majority of Respondents Oppose Glyphosate Stockpiling, Reject Manufacturer Immunity




ICAN Poll: Overwhelming Majority of Respondents Oppose Glyphosate Stockpiling, Reject Manufacturer Immunity

New public opinion data from 2,569 respondents reveals near-unanimous opposition to key provisions of the administration’s glyphosate executive order

AUSTIN, Texas, March 04, 2026 (GLOBE NEWSWIRE) — The Informed Consent Action Network (ICAN) released the results of a public opinion poll conducted in response to the Trump Administration’s executive order directing federal agencies to stockpile glyphosate-based herbicides. The poll, which drew 2,569 respondents, found sweeping opposition to federal stockpiling of glyphosate, near-total rejection of legal immunity for manufacturers, and widespread concern about the integrity of safety research used to justify current policies.

Key Findings

Context and Background
The poll was launched in February 2026 following the administration’s executive order directing federal agencies to ensure an adequate domestic supply of glyphosate and related chemical herbicides as part of national preparedness planning. The order came amid heightened public scrutiny of glyphosate’s safety profile, driven by several converging developments:

Bayer AG, which acquired Monsanto in 2018, has paid more than $10 billion in verdicts and settlements related to claims that its glyphosate-based Roundup herbicide causes cancer — particularly non-Hodgkin’s lymphoma — and continues to face approximately 67,000 active lawsuits. In February 2026, Bayer proposed a $7.25 billion class settlement to resolve current and future claims. (Source: Bloomberg / Insurance Journal, February 17, 2026)

On November 28, 2025, a study published in Regulatory Toxicology and Pharmacology — long cited as a foundational piece of evidence supporting glyphosate’s safety — was formally retracted, raising further questions about the scientific basis for current regulatory positions.

“These results speak for themselves,” said Del Bigtree, founder and CEO of ICAN. “The American public is paying attention. They know about the billions in legal judgments. They know the key safety study has been retracted. They are sending a clear message: they do not support policies that result in stockpiling products with unresolved safety questions or shield corporations from accountability.”

About the Poll
The ICAN Glyphosate Public Opinion Poll was conducted online in February 2026 and distributed through ICAN’s email list, website, and social media channels. A total of 2,569 respondents answered four multiple-choice questions covering awareness of glyphosate litigation, federal stockpiling policy, manufacturer legal immunity, and the impact of a recent study retraction on public trust. Each question offered three response options: Yes, No, or Unsure.

The full results report, including detailed data visualizations and analysis for each question, is available HERE.

Note: This poll reflects the views of ICAN’s engaged audience and is not presented as a statistically representative sample of the broader U.S. population. Results should be interpreted within the context of the respondent base. A complete methodology note is included in the full report.

About ICAN
The Informed Consent Action Network (ICAN) is a 501(c)(3) nonprofit organization focused on scientific integrity within the vaccine and pharmaceutical industries. Through investigations, legal actions, public education, and Freedom of Information campaigns, ICAN works to ensure that government health agencies and corporations are held to the highest standards of transparency and accountability. ICAN is the producer of The HighWire, a weekly investigative news program. Learn more at icandecide.org.

Media Contact: Catharine Layton | press@icandecide.org | 512-522-8739

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/59926f6d-1466-4426-bb25-c75c2697a7c7

CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026




CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT.

Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.

About CytomX Therapeutics, Inc.

CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com

Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com

Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)




Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that it granted equity awards on March 2, 2026, to four newly-hired, non-executive employees. The inducement grants were approved by Galecto’s independent Compensation Committee and were made as material inducements to such individuals’ acceptance of employment with Galecto in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 153,700 shares of the Galecto’s common stock with a 10-year term and an exercise price of $29.58 per share. The options vest as to 25% on the first anniversary of the applicable grant date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Galecto, Inc. Inducement Plan, and the terms and conditions of a stock option agreement.

About Galecto, Inc.

Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.

Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com

Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

Genvor Announces Strategic Expansion into Health and Wellness Market, Leveraging Proprietary AI-Accelerated BioCypher Platform to Develop Consumer Peptide Solutions




Genvor Announces Strategic Expansion into Health and Wellness Market, Leveraging Proprietary AI-Accelerated BioCypher Platform to Develop Consumer Peptide Solutions

Company’s proprietary peptide platform expands beyond agriculture into human recovery, performance, and wellness

Woodland, CA, March 04, 2026 (GLOBE NEWSWIRE) — Genvor, Inc. (OTCQB: GNVR), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health, today announced its formal entry into the human health and wellness sector, marking a significant expansion of its corporate strategy into consumer-focused biological innovation.

The expansion is powered by Genvor’s proprietary BioCypher™ platform, an AI-driven peptide generation engine backed by a library of millions of designed peptides that has already produced dozens of researched lead agricultural candidates across more than a dozen pathogens and multiple areas of crop protection. With health and wellness peptides already engineered within this library, Genvor is now leveraging the BioCypher platform to identify and advance the most promising candidates into safe, effective, and commercially viable consumer health and wellness products.

With global peptide therapeutics and supplements markets experiencing strong growth and projected to reach multi-billion-dollar valuations in the coming decade, Genvor is positioned to apply its deep scientific expertise and proven peptide design capabilities to meet surging consumer demand for science-backed recovery, performance, and wellness solutions. Industry analysts forecast the global peptide supplements market alone to grow from approximately USD $4.1 billion in 2025 to USD $11.2 billion by 2035, driven by rising consumer interest in muscle recovery, immune support, and bioavailable health products.

“Our BioCypher platform has already demonstrated its power across more than a dozen agricultural pathogens and multiple meaningful areas of crop protection,” said Chad Pawlak, Chief Executive Officer of Genvor. “Expanding into consumer health and wellness reflects our ability to unlock what has been in our library since the company’s founding. Advancing these product candidates into consumer markets is a natural evolution that creates multiple revenue pathways from a single platform. This expansion positions us to innovate responsibly while delivering meaningful value to customers, commercial partners and investors.”

Genvor’s BioCypher platform combines computational biology with machine learning to generate novel peptides faster than traditional R&D approaches, designing candidates optimized for both agricultural performance and human bioavailability. The company’s dual-market commercialization model pairs a licensing-first approach in agriculture with a direct-to-consumer model in human health, bringing targeted peptide-based recovery and performance solutions to market through strategic partnerships and retail channels.

Genvor is in discussions with strategic partners who bring authentic credibility, market access, and deep expertise in recovery and performance optimization. The company’s consumer health pipeline also includes applications in anti-aging, daily wellness, and targeted recovery formulations, all leveraging the same BioCypher-designed peptide sequences that underpin its agricultural programs.

As part of this strategic expansion, Genvor also announced a realignment of senior leadership responsibilities. George Stavrides, Executive Vice President of Business Development and Commercialization, will assume expanded oversight of the company’s agricultural commercialization initiatives, focusing on building revenue-producing collaborations and advancing licensing partnerships with Tier-1 agricultural companies. This ensures continuity and growth across Genvor’s established agricultural programs, which span eight crop targets across anti-pathogen and enhanced nutrition applications.

Pawlak will devote increased focus to capital markets strategy and the expansion of Genvor’s consumer peptide platform, including partnership development, research collaborations, and the coordination of regulatory, commercial, and investor interests as the company builds its presence in the health and wellness market.

Genvor welcomes new commercial partners, investors, financial institutions, and strategic collaborators to engage in this dynamic phase of growth as the company advances innovative peptide solutions across agriculture and human health and wellness.

About Genvor

Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Genvor’s proprietary BioCypher platform designs peptides that enhance crop performance, reduce chemical inputs, and support human recovery and wellness. Through strategic partnerships and a dual-market commercialization model, Genvor is advancing peptide science from field to finish line. For more information, visit www.genvor.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations and projections about future events and are not guarantees of future performance. Forward-looking statements include, among others, statements regarding the potential benefits, outcomes, and scope of Genvor’s expansion into the health and wellness market, the development and commercialization of consumer peptide products, the growth of the peptide supplements market, the company’s partnership strategy, and the expected roles and responsibilities of the company’s leadership team. Actual results may differ materially from those expressed or implied. Factors that could cause such differences include, but are not limited to, research results, product development outcomes, regulatory developments, funding availability, market conditions, market adoption, competitive dynamics, and the ability to attract and retain strategic partners. Genvor undertakes no obligation to update or revise forward-looking statements, except as required by law.

Contact:
Carly Scaduto
carly@carlyscadutoconsulting.com

Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference




Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference

BRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the Barclays 28^th Annual Global Healthcare Conference at 2:30 PM ET on Wednesday, March 11, 2026 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera_®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.

CONTACT: Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com

Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer




Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer

• Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer
• Competitive funding award highlights Theolytics’ innovative science and strong clinical development plan
• Application coordinated with several major international clinical centres and world-class partners

Oxford UK, March 4, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has been awarded, pending final negotiation, €8 million in non-dilutive grant funding from Horizon Europe 2025, the European Union’s flagship research and innovation funding programme. Horizon Europe 2025 is supporting high-impact clinical-stage projects aimed at improving patient outcomes and strengthening Europe’s scientific leadership. The grant to Theolytics will provide significant financial support to advance the company’s Phase 2 OCTOPOD-IV clinical trial evaluating THEO-260, its novel therapeutic candidate designed to address unmet needs in patients with advanced ovarian cancer.

Positioned to tackle the complex, immune-suppressed nature of advanced solid tumours, THEO-260 is an oncolytic immunotherapy designed for effective killing of both cancer cells and cancer-associated fibroblasts (CAFs), while inducing immune activation. Platinum-resistant ovarian cancer represents a prototype of a broader category of stroma-rich solid tumours for which THEO-260 is being developed.

Margaret Duffy, CSO and Co-founder of Theolytics, said, “Our collective success with this grant award reflects the extraordinary work being done by the team at Theolytics, and the calibre of our clinical and translational partner centres. The Horizon Europe award validates both the scientific rationale behind our THEO-260 programme and the huge potential of its novel oncolytic and ‘CAF-lytic’ mechanism to address a significant unmet need in stroma-rich solid cancers. By integrating advanced translational analyses into our clinical trial design, we will clinically demonstrate the differentiated mechanism of action of THEO-260 and provide key data to advance this programme and deliver true impact for cancer patients.”

This highly competitive Horizon Europe 2025 award follows a rigorous grant review process and highlights the company’s innovative science, strong technical area expertise, clear clinical development plan and the opportunity for THEO-260 to address a clear unmet patient need.

The grant application was coordinated with several major partners, expert clinical and translational centres involved in the OCTOPOD-IV study and includes the University of Navarra, Catalan Institute of Oncology in Spain; the Princess Margaret Hospital in Toronto, Canada; and The Institute of Cancer Research (ICR) in London, UK. Two thirds of the funds will be received directly by Theolytics to advance the OCTOPOD-IV Phase 2a expansion trial, and the other third will be deployed directly to the partners in support of their work on the trial.

OCTOPOD-IV (NCT06618235) is a first-in-human, multi-centre trial to assess safety, tolerability and preliminary efficacy of THEO-260 in patients with high-grade serous ovarian or endometrioid cancer. In addition, the trial is designed to determine the recommended Phase 2 dose and demonstrate THEO-260’s differentiated cancer/cancer-associated fibroblast-lytic mechanism of action in patients through comprehensive biomarker analysis.

Prof Alan Melcher, Professor of Translational Immunotherapy at The Institute of Cancer Research, London, said, “The differentiated mechanism of action – targeting the stroma and inducing immune activity in the suppressed tumour microenvironment (TME) – of this oncolytic immunotherapy THEO-260 offers the potential to provide an important new treatment option for patients with advanced solid tumours. We are pleased to support the OCTOPOD-IV study, for which the ICR will provide important translational data to assess this novel and promising approach.”

Dr Antonio González, Director of the Department of Medical Oncology and Cancer Center at the Clínica Universidad de Navarra, and President of the Spanish Cooperative Group for Gynaecological Cancer Research, added, “We see many women with advanced platinum-resistant ovarian cancer, whose life expectancy is typically only a year or less. There remains a serious lack of effective treatment options for these women, and so we are hopeful that THEO-260 may bring an advance in therapy that will improve and extend the lives of our patients.”

Recruitment at UK and Spanish clinical sites for OCTOPOD-IV is ongoing and will now expand into further international centres (including additional sites in Spain and Canada). A second clinical trial (OCTOPOD-IP) in the US, which will investigate intraperitoneal (IP) delivery of THEO-260 to advanced ovarian cancer patients, has also been initiated in collaboration with The University of Texas MD Anderson Cancer Center (NCT07211659).

###

About Theolytics

Theolytics is working to develop best-in-class oncolytic immunotherapies. The company has pioneered a new approach to develop efficacious, targeted adenoviral candidates suitable for direct and systemic intravenous delivery.

The company is focused on the advancement of its lead programme THEO-260 in clinical trials with the ambition of providing better outcomes for patients with stroma-rich solid cancers, for whom current treatment options are limited. Additional pipeline programmes in preclinical development include novel candidates developed for colorectal cancer and haematological malignancies where there remains significant unmet need.

Theolytics was founded in 2017, is headquartered in Oxford UK, and is backed by international life sciences investors Taiho Ventures, M Ventures, Oxford Science Enterprises, Epidarex Capital, Sound Bioventures, BGF and Oxford University Innovation.

For more information, please see our website www.theolytics.com

About Horizon Europe 2025 Programme

The ‘Boosting the translation of biotech research into innovative health therapies’ topic, which forms part of the wider Horizon Europe 2025 Health initiative, is designed to accelerate the translation of promising biotech research into clinical development and aims to deliver the following outcomes:

• Faster access to innovative therapies for healthcare providers, researchers and patients
• Increased number of clinical trials evaluating novel biotech therapeutic approaches conducted within the European Union
• Strengthened competitiveness of small and medium-size enterprises (SMEs) in the EU and Associated Countries within the health biotech sector

More information on the Horizon Europe Health initiative can be found here.

Contact

Theolytics

David Apelian, CEO

enquiries@theolytics.com

MEDiSTRAVA

Frazer Hall, Mark Swallow

Theolytics@medistrava.com